-

Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026

Company to host conference call at 8:00 AM ET

Investor Day Scheduled for May 21, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 second quarter ended March 31, 2026, before the opening of the market on May 4, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website prior to the conference call through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Twist will also host an Investor Day for analysts and institutional investors on Thursday, May 21, 2026.

Fiscal 2026 Second Quarter Financial Results Conference Call Details

The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

Investor Day to take place May 21, 2026

Twist will host an Investor Day for analysts and institutional investors on Thursday, May 21, 2026. The event will feature a tour of the company’s manufacturing facility, showcase of automation, multiple customer talks, as well as presentations from several Twist senior leaders highlighting the company’s strategic initiatives, growth opportunities and roadmap ahead. The webcast of management presentations will begin at 11:00 am PT.

Investor Day Webcast Details

The Investor Day will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. The webcast replay will be available for two weeks. Institutional investors and analysts who are interested in attending in person should reach out to Angela Bitting, SVP, Corporate Affairs.

About Twist Bioscience Corporation

At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.

We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.

Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all. For more information about our products and services, please visit www.twistbioscience.com.

Follow us on LinkedIn | X | YouTube | Instagram | Bluesky

Contacts

For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com

Twist Bioscience Corporation

NASDAQ:TWST

Release Versions

Contacts

For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com

Social Media Profiles
More News From Twist Bioscience Corporation

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units (“RSUs”) and up to 13,348 performance stock units (“PSUs”), will be granted to 53 recently hired individuals, in each case as an inducement material to their acceptance of employment w...

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes. “As research in nucleic acid therapeutics and AI-guided protein design and therapeutics discovery accelerate, scientists need a reliable partner to consistently deliver genes rapidly at scale and with more complex sequences,” said Emily M. Leproust, Ph.D., CEO and co-founder...

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal second quarter 2026 earnings report and the investor presentation, or click https://investors.tw...
Back to Newsroom